DUBLIN, Ohio & PRINCETON, N.J.--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, and Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that they have entered into a Biopharmaceutical Development and Manufacturing Agreement. Under this agreement, Laureate will assist in the development and production of Neoprobe’s murine monoclonal antibody CC49, called RIGScan® CR, a tumor-specific targeting agent initially intended for use in treatment of colorectal cancer. Terms of the development and manufacturing agreement were not disclosed.
